Form 4: Mirum Pharmaceuticals SVP Jolanda Howe Reports Stock Sale

Jolanda Howe, SVP, Global Controller of Mirum Pharmaceuticals, reports selling 2,415 shares of common stock at an average price of $44.4484.

Summary

• On March 18, 2025, Jolanda Howe, SVP, Global Controller of Mirum Pharmaceuticals, sold 2,415 shares of common stock.
• The sale was executed at a weighted average price of $44.4484, with individual prices ranging from $44.21 to $44.91.
• Following the transaction, Howe directly owns 2,426 shares of Mirum Pharmaceuticals.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale by an insider under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency of trading by corporate insiders. They provide insight into the actions of company executives and directors, which can be informative to investors.

Stakeholder Impact

• The stock sale by a company insider could have a minor negative impact on shareholder sentiment, although the pre-planned nature of the sale mitigates this concern.

Key Dates

Keywords

Form 4, Mirum Pharmaceuticals, Stock Sale, Insider Trading, Jolanda Howe, MIRM, Rule 10b5-1